ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Astellas Pharma, Inc.

Business Summary

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2021 JPYUSD
Revenue1,249.52B11,781.61M
Gross Profit979,702M9,237.46M
Operating income250,897M2,365.67M
Income before tax144,846M1,365.73M
Net income120,589M1,137.01M
EBITDA323,549M3,050.69M
Diluted EPS64.890.61
Dividends Per Share420.39
Total Assets2,273.62B20,575.81M
Total liabilities887,514M8,031.80M
Total equity1,386.11B12,544.02M
Operating cash flow307,880M2,902.95M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 1,311.66B 1,300.31B 1,306.34B 1,300.84B 1,249.52B
Gross Profit 955,325M 970,228M 979,086M 1,002.94B 979,702M
Operating income 276,419M 271,241M 280,141M 279,419M 250,897M
Income before tax 281,769M 218,113M 248,967M 247,010M 144,846M
Net income 218,701M 164,679M 222,265M 195,411M 120,589M
EBITDA 340,210M 336,104M 343,599M 345,815M 323,549M
Diluted EPS 103.55 81.02 114.94 104.07 64.89
Dividends Per Share 34 36 38 40 42
Total Assets 1,814.07B 1,858.20B 1,897.64B 2,315.16B 2,273.62B
Total liabilities 540,614M 583,608M 639,252M 1,026.00B 887,514M
Total equity 1,271.81B 1,268.28B 1,258.39B 1,289.16B 1,386.11B
Operating cash flow 237,230M 314,463M 261,428M 224,060M 307,880M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 12,112.80M 11,732.27M 11,780.07M 11,964.43M 11,781.61M
Gross Profit 8,822.11M 8,754.00M 8,828.97M 9,224.49M 9,237.46M
Operating income 2,552.63M 2,447.30M 2,526.19M 2,569.94M 2,365.67M
Income before tax 2,602.04M 1,967.95M 2,245.07M 2,271.86M 1,365.73M
Net income 2,019.63M 1,485.83M 2,004.28M 1,797.28M 1,137.01M
EBITDA 3,141.72M 3,032.54M 3,098.42M 3,180.61M 3,050.69M
Diluted EPS 0.95 0.73 1.03 0.95 0.61
Dividends Per Share 0.31 0.32 0.34 0.36 0.39
Total Assets 16,279.92M 17,472.54M 17,144.58M 21,445.68M 20,575.81M
Total liabilities 4,851.60M 5,487.61M 5,775.41M 9,503.95M 8,031.80M
Total equity 11,413.53M 11,925.61M 11,369.16M 11,941.71M 12,544.02M
Operating cash flow 2,190.74M 2,837.28M 2,357.44M 2,060.78M 2,902.95M

Valuation Measures

Mar 2021
PER26.21
ROA5.25%
ROE9.01%
Operating margin20.07%
Profit margin9.65%

Key executives

  • President, CEO & Representative Director: Kenji Yasukawa
  • CFO, Representative Director & Vice President: Naoki Okamura
  • Chief Scientific Officer: Yoshitsugu Shitaka
  • Head-Business Administration & Compliance: Fumiaki Sakurai
  • Senior VP-Product & Portfolio Strategy: Claudia Mitchell

Shareholders

  • Nomura Asset Management Co., Ltd. (6.0%)
  • Wellington Management Co. LLP (3.6%)
  • Nippon Life Insurance Co. (3.4%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.4%)
  • Nikko Asset Management Co., Ltd. (3.2%)
  • BlackRock Fund Advisors (3.2%)
  • Daiwa Asset Management Co. Ltd. (2.8%)
  • The Vanguard Group, Inc. (2.5%)
  • Norges Bank Investment Management (1.6%)
  • BlackRock Japan Co., Ltd. (1.5%)

Contact Details

  • Website:http://www.astellas.com
  • Address: 2-5-1 Nihonbashi-Honcho, Chuo-Ku, Tokyo, 103-8411, Japan
  • Phone: +81.3.3244.3000

Related Companies

  • Astellas Pharma, Inc. /5 Legacy Products/
  • Astellas Pharma, Inc. /Milrila Injection Product/
  • OSI Pharmaceuticals, LLC
  • Representative Office of Astellas Pharma Singapore
  • Astellas Pharma Malaysia Sdn. Bhd.
  • Astellas Green Supply, Inc.
  • Xyphos Biosciences, Inc.
  • Iota Biosciences, Inc.
  • Astellas Pharma, Inc. /Agensys Research Facilities/
  • Astellas Pharma, Inc. /16 Long Listed Products/
  • Astellas Farma Colombia
  • Astellas Pharma Director Incentive Plan
  • Quethera Ltd.
  • PT Astellas Pharma Indonesia
  • Astellas Pharma ZAO
  • Astellas Pharma Hong Kong Co., Ltd.
  • Astellas Pharma India Pvt Ltd.
  • Astellas Pharma (Thailand) Co., Ltd.
  • Astellas Pharma Australia Pty Ltd.
  • Astellas Pharma Singapore Pte Ltd.
  • Astellas Pharma Tech Co., Ltd.
  • Astellas Gene Therapies, Inc.
  • Mitobridge, Inc.
  • Astellas Pharma China, Inc.
  • Perseid Therapeutics LLC
  • GPDC Partnership
  • Astellas Pharma Philippines, Inc.
  • Astellas Pharma Co. Ltd.
  • Astellas Pharma Canada, Inc.
  • Fujisawa Taiwan Co. Ltd.

Competitors

  • AstraZeneca PLC
  • Roche Holding Ltd
  • Hanmi Pharmaceutical Co., Ltd.
  • CrystalGenomics Inc.
  • Antares Pharma, Inc.
  • Alembic Pharmaceuticals Limited
  • AbClon, Inc.
  • Ipsen SA
  • DexTech Medical AB
  • Poseida Therapeutics, Inc.
  • OSE Immunotherapeutics SA
  • Golden Biotechnology Corp.
  • MedPacto, Inc.
  • Bicycle Therapeutics Plc Sponsored ADR
  • Agenus Inc.
  • LegoChem Biosciences, Inc.
  • DongKoo Bio & Pharm Co. Ltd.
  • Akebia Therapeutics, Inc.
  • Sophiris Bio Inc.
  • Cullinan Oncology, Inc.
  • GlycoMimetics, Inc.
  • PTC Therapeutics, Inc.
  • Agios Pharmaceuticals, Inc.
  • Biophytis SA
  • ERYTech Pharma SA
  • Keros Therapeutics, Inc.
  • Kura Oncology, Inc.
  • LogicBio Therapeutics, Inc.
  • Synthetic Biologics, Inc.
  • Angion Biomedica Corp.
Last Updated on 18 Oct, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more